Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867086 · ClinicalTrials.gov registry record · Phase 2
Salvage Ovarian FANG™ Vaccine + Carboplatinum
A Phase 2 study, sponsored by Gradalis.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01867086 is a Phase 2 study that has completed, run by Gradalis. The registered enrollment target is 1 participants.
The verdict
NCT01867086, a Phase 2 study, has completed, sponsored by Gradalis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with carboplatinum. All patients will have Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking. Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2/3 hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection, once every 3 weeks.
Interventions
- BIOLOGICAL Vigil™ Vaccine
- DRUG Carboplatinum
- DRUG Carboplatinum and Taxol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-04-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867086
The ClinicalTrials.gov registry entry for NCT01867086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gradalis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vigil™ Vaccine is the first listed.
NCT01867086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01867086 about?
NCT01867086 is a clinical study titled "Salvage Ovarian FANG™ Vaccine + Carboplatinum". This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with carboplatinum. All patients will have Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking. Patients meeting eligibility criteria will receive either carboplatinum alone...
What is the current status of trial NCT01867086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2013-06. Estimated completion is 2016-04-08.
What interventions are being tested in trial NCT01867086?
The interventions under investigation include: Vigil™ Vaccine (BIOLOGICAL), Carboplatinum (DRUG), Carboplatinum and Taxol (DRUG).
Who is sponsoring clinical trial NCT01867086?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.